Walter Woltosz Sells 4,177 Shares of Simulations Plus (NASDAQ:SLP) Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter Woltosz sold 4,177 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total transaction of $77,023.88. Following the completion of the transaction, the director owned 3,202,131 shares of the company’s stock, valued at $59,047,295.64. This represents a 0.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Simulations Plus Price Performance

Shares of SLP traded down $0.03 during midday trading on Monday, reaching $18.36. The stock had a trading volume of 340,704 shares, compared to its average volume of 389,171. Simulations Plus, Inc. has a 52 week low of $11.09 and a 52 week high of $21.01. The firm’s 50 day moving average price is $16.17 and its 200-day moving average price is $15.49. The company has a market capitalization of $370.87 million, a P/E ratio of -5.87 and a beta of 1.30.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Thursday, April 9th. The technology company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.27 by $0.08. Simulations Plus had a negative net margin of 77.96% and a positive return on equity of 16.21%. The firm had revenue of $24.29 million for the quarter, compared to analysts’ expectations of $21.66 million. On average, equities analysts forecast that Simulations Plus, Inc. will post 0.8 earnings per share for the current year.

Institutional Investors Weigh In On Simulations Plus

A number of large investors have recently bought and sold shares of SLP. Raymond James Financial Inc. acquired a new position in shares of Simulations Plus during the 2nd quarter valued at about $25,000. Quarry LP bought a new stake in Simulations Plus during the third quarter worth approximately $28,000. PNC Financial Services Group Inc. boosted its position in Simulations Plus by 59.3% during the first quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company’s stock worth $53,000 after purchasing an additional 1,669 shares during the period. Fifth Third Bancorp acquired a new position in Simulations Plus in the 1st quarter valued at $54,000. Finally, Caitong International Asset Management Co. Ltd lifted its position in Simulations Plus by 343.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock worth $73,000 after acquiring an additional 3,084 shares during the last quarter. 78.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SLP has been the subject of a number of analyst reports. Weiss Ratings raised shares of Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, June 5th. TD Cowen dropped their target price on shares of Simulations Plus from $19.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday, April 10th. Craig Hallum lowered shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price target on the stock. in a report on Thursday, June 18th. Wall Street Zen downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, William Blair lowered shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $20.90.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.